Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergio Valente

Showing results (1-10 of 155) with videos related to

Pageof 16
Sort By:
Expert Opinion on Therapeutic Patents|January 9, 2014
Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013)Sergio Valente, Antonello Mai
Current Topics in Medicinal Chemistry|August 26, 2015
DNA Methyltransferases Inhibitors from Natural SourcesClemens Zwergel, Sergio Valente, Antonello Mai
Expert Opinion on Therapeutic Patents|December 2, 2014
Sirtuin modulators: an updated patent review (2012 - 2014)Paolo Mellini, Sergio Valente, Antonello Mai
Hand (New York, N.Y.)|June 19, 2021
Distal-Ulna Stump Stability: The Role of Distal Interosseous Membrane: Myth or Reality? Anatomical ResearchLuciano A Poitevin, Daniel Postan, Sergio Valente
Expert Opinion on Therapeutic Patents|March 29, 2016
LSD1 inhibitors: a patent review (2010-2015)Giulia Stazi, Clemens Zwergel, Sergio Valente, et al.
Journal of Medicinal Chemistry|January 23, 2024
SIRT3 Activation a Promise in Drug Development? New Insights into SIRT3 Biology and Its Implications on the Drug Discovery ProcessChiara Lambona, Clemens Zwergel, Sergio Valente, et al.
Expert Opinion on Drug Discovery|April 22, 2015
Emerging approaches for histone deacetylase inhibitor drug discoveryClemens Zwergel, Sergio Valente, Claus Jacob, et al.
Journal of Medicinal Chemistry|July 10, 2025
Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic PotentialAlessia Raucci, Clemens Zwergel, Sergio Valente, et al.
Expert Opinion on Therapeutic Patents|April 11, 2017
EZH2 inhibitors: a patent review (2014-2016)Giulia Stazi, Clemens Zwergel, Antonello Mai, et al.
International Journal of Oncology|May 3, 2014
Evaluation of ∆2-pioglitazone, an analogue of pioglitazone, on colon cancer cell survival: Evidence of drug treatment association with autophagy and activation of the Nrf2/Keap1 pathwaySophie Huber, Sergio Valente, Patrick Chaimbault, et al.
Pageof 16

Showing results (1-10 of 155) with videos related to

Sort By:
Pageof 16
Expert Opinion on Therapeutic Patents|January 9, 2014
Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013)Sergio Valente, Antonello Mai
Current Topics in Medicinal Chemistry|August 26, 2015
DNA Methyltransferases Inhibitors from Natural SourcesClemens Zwergel, Sergio Valente, Antonello Mai
Expert Opinion on Therapeutic Patents|December 2, 2014
Sirtuin modulators: an updated patent review (2012 - 2014)Paolo Mellini, Sergio Valente, Antonello Mai
Hand (New York, N.Y.)|June 19, 2021
Distal-Ulna Stump Stability: The Role of Distal Interosseous Membrane: Myth or Reality? Anatomical ResearchLuciano A Poitevin, Daniel Postan, Sergio Valente
Expert Opinion on Therapeutic Patents|March 29, 2016
LSD1 inhibitors: a patent review (2010-2015)Giulia Stazi, Clemens Zwergel, Sergio Valente, et al.
Journal of Medicinal Chemistry|January 23, 2024
SIRT3 Activation a Promise in Drug Development? New Insights into SIRT3 Biology and Its Implications on the Drug Discovery ProcessChiara Lambona, Clemens Zwergel, Sergio Valente, et al.
Expert Opinion on Drug Discovery|April 22, 2015
Emerging approaches for histone deacetylase inhibitor drug discoveryClemens Zwergel, Sergio Valente, Claus Jacob, et al.
Journal of Medicinal Chemistry|July 10, 2025
Advancements in Hydrazide-Based HDAC Inhibitors: A Review of Recent Developments and Therapeutic PotentialAlessia Raucci, Clemens Zwergel, Sergio Valente, et al.
Expert Opinion on Therapeutic Patents|April 11, 2017
EZH2 inhibitors: a patent review (2014-2016)Giulia Stazi, Clemens Zwergel, Antonello Mai, et al.
International Journal of Oncology|May 3, 2014
Evaluation of ∆2-pioglitazone, an analogue of pioglitazone, on colon cancer cell survival: Evidence of drug treatment association with autophagy and activation of the Nrf2/Keap1 pathwaySophie Huber, Sergio Valente, Patrick Chaimbault, et al.
Pageof 16